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Background: Osteosarcoma (OSA) is the most common primary bone tumor of dogs and carries a poor prognosis
despite aggressive treatment. An improved understanding of the biology of OSA is critically needed to allow for
development of novel diagnostic, prognostic, and therapeutic tools. The surface-exposed proteome (SEP) of a
cancerous cell includes a multifarious array of proteins critical to cellular processes such as proliferation, migration,
adhesion, and inter-cellular communication. The specific aim of this study was to define a SEP profile of two
validated canine OSA cell lines and a normal canine osteoblast cell line utilizing a biotinylation/streptavidin system
to selectively label, purify, and identify surface-exposed proteins by mass spectrometry (MS) analysis. Additionally,
we sought to validate a subset of our MS-based observations via quantitative real-time PCR, Western blot and semi-
quantitative immunocytochemistry. Our hypothesis was that MS would detect differences in the SEP composition
between the OSA and the normal osteoblast cells.
Results: Shotgun MS identified 133 putative surface proteins when output from all samples were combined, with
good consistency between biological replicates. Eleven of the MS-detected proteins underwent analysis of gene
expression by PCR, all of which were actively transcribed, but varied in expression level. Western blot of whole cell
lysates from all three cell lines was effective for Thrombospondin-1, CYR61 and CD44, and indicated that all three
proteins were present in each cell line. Semi-quantitative immunofluorescence indicated that CD44 was expressed
at much higher levels on the surface of the OSA than the normal osteoblast cell lines.
Conclusions: The results of the present study identified numerous differences, and similarities, in the SEP of canine
OSA cell lines and normal canine osteoblasts. The PCR, Western blot, and immunocytochemistry results, for the
subset of proteins evaluated, were generally supportive of the mass spectrometry data. These methods may be
applied to other cell lines, or other biological materials, to highlight unique and previously unrecognized
differences between samples. While this study yielded data that may prove useful for OSA researchers and
clinicians, further refinements of the described techniques are expected to yield greater accuracy and produce a
more thorough SEP analysis.
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Osteosarcoma (OSA) is the most common primary bone
tumor of dogs with >8000 cases diagnosed annually in
the United States of America [1]. Despite aggressive
treatment incorporating surgery, radiation therapy, and/
or chemotherapy, survival times remain poor. Over 90%
of canine patients undergoing standard-of-care treat-
ment, without clinically detectable metastasis at time of
diagnosis, will ultimately succumb to metastatic disease
[1,2]. Overall reported median survival times are 235-
366 days, and 1- and 2-year survival rates range from
33-65% and 16-28%, respectively [1-4]. The development
of effective tools to diagnose and treat OSA is essential
for mitigating the negative impact of this disease on both
canine patients and their owners.
The extracellular surface of a cancerous cell includes a
multifarious array of proteins that are critical to processes
such as cell proliferation, migration, adhesion, and inter-
cellular communication. Collectively, this group of pro-
teins can be referred to as the surface-exposed proteome
(SEP). Abnormalities in the SEP are central to the biologic
behavior of cancer [5]. Recognized abnormalities in can-
cerous cells include changes in the expression level of par-
ticular proteins, the presence of unusual protein isoforms,
and alterations in post-translational modification patterns
(e.g. phosphorylation or glycosylation) [5,6].
Despite OSA’s considerable clinical impact, a compara-
tive analysis of the SEP between canine osteosarcoma and
normal osteoblast cells has not been described in the vet-
erinary literature. Isolated reports of specific abnormalities
in canine OSA are limited to focused evaluations of spe-
cific proteins, often prompted by discoveries in other neo-
plasms or species. Examples of such proteins include:
survivin [7], cathepsin K [8], Met [9-11], EGFR [9], Ron
[9], p53 [12,13], HER-2 [14], HGF [10,11], IGF-1 and IGF-
1R [15], MMP-2 and MMP-9 [16,17], and ezrin [18]. A
more global analysis of the SEP differences between OSA
and normal osteoblast cells holds the potential of identify-
ing unique and previously unrecognized features of OSA
that can be exploited in treatment, diagnostic, and/or
prognostic capacities [5,6,19-23].
While there are many different methods available for
enriching plasma membrane proteins, labeling surface
proteins with biotin is a popular approach because of
the availability of membrane-impermeable biotinylation
reagents and the strong association between biotin and
streptavidin, which is used for affinity purification of
biotin-labeled molecules [24]. These two attributes make
it feasible to selectively label surface proteins, and then
use denaturing conditions to extract total protein from
labeled cells and affinity purify the biotinylated fraction.
The purified surface proteins can then be enzymatically
digested with trypsin and the resulting peptides identi-
fied by mass spectrometry (MS). MS-based proteomicshas been applied to numerous cancer biomarker discov-
ery projects and enables protein-level investigations
reflecting many of the biological processes relevant to
cancer growth and invasion [20,21,25,26].
The specific aim of our study was to define a profile of
proteins that compose the SEP of two validated canine
OSA cell lines and a normal canine osteoblast cell line
utilizing the aforementioned biotinylation/streptavidin
system to selectively label, purify, and identify surface-
exposed proteins by LC-MS/MS analysis. Additionally,
we sought to validate a subset of our MS-based observa-
tions via quantitative real-time PCR (qRT-PCR) and
antibody-based techniques. Our hypothesis was that MS
would detect differences in the SEP composition be-
tween the OSA and the cultured normal osteoblast cells.
Results
Identification of surface-exposed proteins
The biotin-labeled surface proteins from each cell line
were extracted and visualized by SDS-PAGE and Western
blot (Figure 1). The gross comparison of biotinylation pat-
terns indicated that the complement of surface-exposed
proteins from the POS and HMPOS cell lines appeared
similar, while the surface proteome of the CnOb cell line
appeared to be markedly different. Following the affinity
purification and proteolysis of the biotinylated proteins,
analysis of the peptides by shotgun MS identified a total of
133 putative surface proteins when outputs from all
samples and replicates were combined (Additional file 1:
Table S1). Protein identifications were largely consistent
between biological replicates (Additional file 2: Table S2).
Based on their potential relevance to cancer biology, a
subset of the identified proteins was selected for inclusion
in Table 1, with their relative spectral counts expressed as
a percentage of total spectra. Several proteins that are
known to be associated with the cell surface and/or inter-
act with the extracellular matrix were detected in all three
cell lines, such as Fibronectin, Vitronectin, CYR61 and
Annexin A2 [27-30]. Several additional surface proteins
were found to be detected in abundance in one cell line,
but poorly detected or absent in the others. For example,
peptides originating from Thrombospondin-1 were ob-
served in abundance from CnOb samples, but were not
observed in any of the replicates from the POS or
HMPOS cell lines. Similarly, both Chondroitin Sulfate
Proteoglycan 4 (CSPG4) and CD109 were detected from
POS samples, but were not detected in the other samples.
qRT-PCR
Eleven of the proteins that were detected by MS were se-
lected for secondary analysis of gene expression by qRT-
PCR, the results of which are summarized in Figure 2.
These eleven proteins were selected on the basis of their
relevance to cancer biology and the availability of
Figure 1 Biotinylation of cell lines. (A) Silver stain of total protein
from biotin treated and non-biotin treated cultured normal canine
osteoblasts (CnOb) and two validated canine osteosarcoma cell lines
(POS and HMPOS). (B) Anti-biotin Western blot of all biotinylated
proteins from biotin treated and non-biotin treated CnOb, POS, and
HMPOS cell line samples.
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nine targets. Active transcription of all of the selected
genes was detected by qRT-PCR, indicating that all of
these genes are indeed expressed in the cell lines
used in this study. Expression was normalized to
GAPDH and the biological replicates were generally
in close agreement between samples, with few minor
variations (Additional file 3: Table S3).Western blot
Following validation and quantification of gene expres-
sion by qRT-PCR, five proteins were selected for further
validation by Western blot: Thrombospondin-1, CYR61,
CD44, Notch2 and Plexin B2. Due to the dearth of vali-
dated, canine-specific antibodies, these targets wereselected based on the availability of antibodies that were
likely to be cross-reactive with canine proteins. The anti-
bodies against Notch2 and Plexin B2 were found to have
poor target specificity towards the canine proteins in
our samples and were excluded from the final figure.
Western blots of whole cell lysates from all three cell
lines was effective for Thrombospondin-1, CYR61 and
CD44, and indicated that all three proteins were
present in each cell line, albeit with differential abun-
dance (Figure 3).
Immunocytochemistry
To assess surface-localization of the selected proteins,
an on-cell Western blot approach was used to visualize
and quantify the proteins on the surface of live cells. Of
the five experimental antibodies tested in this study, only
the anti-CD44 antibody was validated for either im-
munocytochemistry or flow cytometry applications, and
only with murine cells. Not surprisingly, only the anti-
CD44 antibody was observed to bind, at detectable
levels, to the cell surface of the cell lines used in this
study. The fluorescent signal from anti-CD44 was quan-
tified on a fluorescent scanner and normalized to the ap-
proximate number of cells, as measured by the signal
intensity from the nuclear stain Hoecsht 33342. This
semi-quantitative ICC analysis indicated that all three
cell lines expressed CD44 on their surface, although it
was much less abundant on the surface of CnOb cells
compared to POS or HMPOS cells (Figure 4). The
complete ICC results for all of the tested antibodies are
summarized in Additional file 4.
Discussion
The present study successfully employed a method of
biotinylation/streptavidin enrichment with MS-based
peptide sequencing to selectively label, purify, and iden-
tify surface exposed proteins from two validated canine
OSA cell lines and a commercially available normal
osteoblast line. A total of 133 putative surface-exposed
proteins were identified when outcome from all cell lines
was combined. Significant differences in SEP compos-
ition, and many similarities, were observed between the
canine OSA cell lines (POS, HMPOS) and the normal
canine osteoblast cell line (CnOb). Based on these obser-
vations, we conclude that MS can effectively detect SEP
differences between cultured canine OSA and normal
osteoblast cell lines.
When evaluating the list of 133 proteins identified via
these methods, it is important to bear in mind that
confident quantification of protein levels is not possible
with this methodology because relative quantities can be-
come skewed during the enrichment process, depending
on the protein. Furthermore, this analysis invariably rep-
resents only a fraction of the total SEP; as a
Table 1 Subset of mass spectrometry-identified surface proteins of cell lines
Protein name Gene name NCBI Ref Sequence CnOb POS HMPOS
Fibronectin FN1 XP_536059 0.55 0.16 0.14
Annexin 2 ANXA2 NP_001002961 0.15 0.33 0.43
Protein CYR61 CYR61 XP_537091 0.1 0.01 0.48
Vitronectin VTN XP_854040 0.1 0.11 0.13
Serpin Peptidase Inhibitor SERPINH1 NP_001159360 0.17 0.37 0.24
Thrombospondin-1 THBS1 XP_544610 1.1 0 0
Chondroitin sulfate proteoglycan 4 CSPG4 XP_544783 0 2.0 0
CD109 antigen isoform 3 CD109 XP_532205 0 0.21 0
Neuropilin-1 isoform 2 NRP1 XP_535142 0 0.12 0
Glypican-4 GPC4 XP_549265 0 0.11 0
4 F2 cell-surface antigen heavy chain SLC3A2 XP_540898 0 0.11 0
Cysteine-rich secretory protein LCCL domain-containing 2 CRISPLD2 XP_546797 0 0 0.06
Integrin Beta-1 ITGB1 XP_535143 0.07 0.08 0
Plexin B2 PLXNB2 XP_531689 0 0.77 0.11
CD44 antigen precursor CD44 NP_001183951 0 0.15 0.07
Ephrin type-A receptor 2 isoform 1 EPHA2 XP_544546 0 0.35 0.06
Inactive tyrosine-protein kinase 7 isoform A PTK7 XP_538929 0 0.42 0.02
C-type mannose receptor 2 MRC2 XP_003435244 0 0.22 0.01
Delta-sarcoglycan SGCD XP_854897 0 0.16 0.01
Notch homolog protein 2 isoform 1 NOTCH2 XP_540266 0 0.08 0.02
A subset of the surface-exposed proteins identified by mass spectrometry in cultured normal canine osteoblasts (CnOb) and two validated canine osteosarcoma
cell lines (POS and HMPOS), with their relative spectral counts expressed as a percentage of total spectra.
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mentary sample processing methods, standards, and con-
trols. Despite these limitations, the primary benefit of
MS-based proteomic techniques, such as the one de-
scribed in this report, is the ability to identify numerous
previously unrecognized SEP differences between sam-
ples in a high-throughput fashion. This latitudinousFigure 2 Quantitative real-time PCR of cell lines. Quantitative real-time
surface proteins detected by mass spectrometry of cultured normal canine
(POS and HMPOS).analysis of the SEP can highlight novel targets for future
diagnostic, prognostic and therapeutic methods [5,6,19].
MS-based proteomics is a relatively new tool in canine
OSA research, and due to the limited information on this
specific disease, we sought to validate a subset of our MS
observations via secondary methods. These included qRT-
PCR, Western blot, and immunocytochemistry. ThePCR indicating relative expression of selected genes corresponding to
osteoblasts (CnOb) and two validated canine osteosarcoma cell lines
Figure 3 Western blot of cell lines. Western blot of whole cell
lysate to detect the presence of CD44, Thrombospondin-1 and
CYR61 in cultured normal canine osteoblasts (CnOb) and two
validated canine osteosarcoma cell lines (POS and HMPOS).
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tory, but they occasionally contradictory, and highlighted
some important limitations of the MS data sets. These re-
sults are summarized for a selected group of proteins in
Table 2. For example, a negative result for an antigen in
the MS data was not necessarily indicative that the target
was absent, which was illustrated by our confirmation ofFigure 4 anti-CD44 immunocytochemistry on live cell lines. A. On-cell
surface of live CnOb (normal canine osteoblast cell line), POS and HMPOS (
density on cell surface indicating increased surface expression in both oste
(CnOb). Quantification measures mean fluorescent intensity (MFI) of anti-CD
(quantified by nuclear stain).CD44. Overall, the limited scope of this study means that
the resulting data is inherently incomplete. However, these
initial results also indicate that further improvements in
sample processing methods, mass spectrometry technolo-
gies, and canine-specific antibodies will improve the feasi-
bility and utility of this type of analysis.
Our initial supportive experiment was qRT-PCR analysis
of 11 of the 133 MS-identified surface-proteins. These 11
proteins were selected based on their known roles in can-
cer biology and apparent differences in abundance, as
measured by MS spectral counts. Our analysis revealed
that transcripts for all 11 genes were detected in each of
the 3 cell lines, indicating that each of these genes were in-
deed expressed, and that each protein was potentially pro-
duced by each cell line. Protein quantification using
spectral counting (label free approach) is considered to be
semi-quantitative and the accuracy is based on the length
of the protein, reproducibility of the sample preparation
techniques, and LC separation [31]. In this study, because
affinity enrichment was incorporated into the sample
preparation, the relative abundance of the proteins deter-
mined by spectral counting can be misleading. Bearing
this limitation in mind, the expression levels of several ofWestern blot image showing binding of anti-CD44 antibody to the
canine osteosarcoma cell lines). B. Semi-quantitative analysis of CD44
osarcoma cell lines (POS and HMPOS), relative to normal osteoblasts
44 staining, normalized to the approximate number of cells
Table 2 Summary of observations for selected surface
proteins
Protein name Mass spec qRT-PCR Western blot ICC
Thrombospondin-1
CnOb D High High N/A
POS ND Low Mid N/A
HMPOS ND Low Low N/A
CD44
CnOb ND High Low Low
POS D Low High High
HMPOS D Low Mid High
CYR61
CnOb D High High N/A
POS D Low High N/A
HMPOS D Low Low N/A
Plexin B2
CnOb ND Low N/A N/A
POS D High N/A N/A
HMPOS D Mid N/A N/A
Notch-2
CnOb ND Low N/A N/A
POS D Mid N/A N/A
HMPOS D High N/A N/A
A summary of observations for a subset of the surface-exposed proteins
identified by mass spectrometry in cultured normal canine osteoblasts (CnOb)
and two validated canine osteosarcoma cell lines (POS and HMPOS) and the




High, Mid, Low = relative expression levels observed.
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surface, as measured by MS. Most notable among these
was Thrombospondin-1, which was detected in unique
abundance from CnOb samples, and whose transcript was
also expressed at much higher levels in CnOb cells than in
POS or HMPOS cells. At the same time, the apparent pro-
tein surface abundance did not closely match gene expres-
sion data for several of the targets. These differences may
arise from differences in post-transcriptional regulation
and/or protein trafficking to the cell surface, or they may
be artifacts of the experimental method. While qRT-PCR
demonstrates which genes are expressed and is an indica-
tor of which proteins are likely to be more or less abun-
dant, qRT-PCR is not a direct indicator of the abundance
and localization of the corresponding proteins.
Western blot analysis demonstrated that the proteins
Thrombospondin-1, CYR61 and CD44 were present at
varying levels in all 3 cell lines. These results are com-
patible with the qRT-PCR results, indicating that these
genes are both expressed and translated into protein in
the cell lines studied. Again, the results were mostconsistent for Thrombospondin-1 protein, which was
observed by Western Blot to be most abundant in the
CnOb sample. Our MS analysis did not detect
thombospondin-1 in the OSA cell lines, although the
qRT-PCR and Western Blot results do indicate that this
gene is transcribed and translated in the OSA cell lines,
albeit at much lower levels than in CnOb. Additionally,
CD44 was detected by qRT-PCR and Western blot in all
three cell lines, but was not observed by MS in the
CnOb cell line. The Western blot analysis represents all
the proteins in the cells (whole cell lysate) whereas our
MS-based SEP analysis is designed to specifically target
the cell surface proteins. Therefore, the observed differ-
ences between Western blot results and MS findings
may be due to changes in the protein localization with
the cells, or they may represent limitations of our
methods. Importantly, none of the proteins identified by
MS were found to be absent in any cell line by Western
blot (i.e. MS did not spuriously report presence of the
three proteins, as verified by Western blot).
Immunocytochemistry represents the most direct
method for confirming the surface localization of the
proteins in question. However, the lack of validated anti-
bodies for use with canine cells limits the population of
proteins that could be confirmed using this technique.
While all five of our antibodies were tested for potential
reactivity, only one (αCD44) was found to bind to the
surface of any of the cell lines, at a detectable level. This
was result was not surprising because only the αCD44
was validated for flow cytometry applications. We ob-
served positive CD44 staining for all of the cell lines, al-
though the signal was much greater in the OSA lines
compared to the CnOb cells. These results are largely
consistent with our MS-based SEP analysis and are com-
patible with our Western blot observations. A previous
study, using methods other than MS, has also demon-
strated presence of CD44 on the cell surface of cultured
canine OSA cells [32]. Furthermore, the CD44 immuno-
cytochemistry findings suggest gene expression levels
(assessed by qRT-PCR) and presence of CD44 in the
whole cell lysate (assessed by Western blot) may not be
indicative of concentration of the protein in question at
the cellular surface—an observation that supports the
selectivity of the biotin/streptavidin surface-protein en-
richment technique employed in the present study.
Although the 133 proteins identified in this study rep-
resent a significant contribution to the study of canine
OSA biology, they do not represent the entire SEP of
these cells. A more comprehensive survey of the SEP
composition could be achieved with the addition of
complementary sample processing methods. For ex-
ample, our method used amine-reactive biotinylation
followed by Trypsin digestion of the recovered proteins
to generate peptides for analysis. A more thorough SEP
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agent (e.g. biotin hydrazide) [33] and/or protease (e.g.
Glu-C) [34,35]. The addition of these methods would
generate complementary data sets, ultimately increasing
the depth, breadth, and accuracy of the analysis. Also,
simply increasing the physical amount of sample ana-
lyzed for each cell line would be expected to yield more
peptides for detection via MS, which would in turn in-
crease the detection rate for proteins that exist in low
quantities on the cell surface.
Conclusions
In conclusion, the results of the present study identified
numerous similarities and differences in the SEP be-
tween cultured canine OSA cell lines and cultured nor-
mal canine osteoblasts. The subset of these findings
evaluated via secondary techniques including qRT-PCR,
Western blot, and immunocytochemistry were found to
be generally supportive of the mass spectrometry data,
although the inconsistencies also demonstrate the limita-
tions of this analysis (Table 2). These methods may be
applied to other cell lines, or other biological materials,
to highlight unique and previously unrecognized and un-
expected differences between samples. While this study
yielded data that may prove useful for OSA researchers
and clinicians, further refinements of the described tech-
niques are expected to yield greater accuracy and more
comprehensive data sets.
Methods
Identification of surface-exposed proteins
The canine osteosarcoma cell lines POS and HMPOS
[36] were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum and the normal canine
osteoblast cell line, CnOb (Cell Applications, San Diego,
CA), was cultured in canine osteoblast medium (Cell
Applications, San Diego, CA). All cells were maintained
in a humidified incubator with 5% CO2 at 37°C.
For all biotinylation experiments, cells were grown to
~80% confluency in T75 tissue culture flasks (Corning
Inc, Corning, NY). Prior to biotinylation, cells were
washed 5 times for 5 min with 10 mL Hanks Buffered Salt
Solution (HBSS). The membrane-impermeable biotiny-
lation reagent Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL)
was used to covalently label the surface-exposed proteins
from live cultures of CnOb, POS and HMPOS cells: 5 mg
of Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) was
dissolved in 10 mL of HBSS and added to each flask. For
negative controls (no biotinylation), 10 ml of plain HBSS
was added to each flask. The biotinylation reaction was
carried out in the tissue culture vessel, with gentle shak-
ing, for 30 minutes at 4°C. Next, the biotinylation solution
was removed and the reaction was quenched by the
addition of HBSS supplemented with 10 mM glycine,which was incubated at room temperature for 20 minutes
with gentle shaking. Cells were then washed twice with
10 mL of HBSS for 5 minutes at room temperature. Cell
viability was verified on control samples with a live/dead
stain (Invitrogen). For affinity purification experiments,
the cells from each flask were harvested into 5 mL of
Guanidinium Lysis Buffer (GLB) (140 mM NaCl, 10 mM
KCl, 20 mM NaPhosphate, 10 mM EDTA, 2 mM EGTA,
0.1% Tween-20, 6 M Guanidinium HCl, pH 7.2). For
Western Blot experiments, cells were harvested into
4 ml of RIPA buffer (Sigma, Saint Louis, MO) supple-
mented with protease inhibitor cocktail (Fermentas,
Waltham, MA).
Insoluble debris in the whole cell lysate was pelleted
by centrifugation for 10 minutes at 9,400 RCF at 4°C.
DNA and other soluble biopolymers were removed by
syringe filtration through a 0.2 μm filter. From each
sample, 3 ml of lysate in GLB buffer was transferred to a
clean tube and 100 μl of Streptavidin-coated C1
Dynabeads (Life Technologies, Grand Island, NY) was
added to each tube. Samples were incubated at 23°C
with agitation for 1 hr. Samples were washed twice for
10 minutes each with 1 ml of GLB and were then
washed twice for 30 minutes each with WB-PBS
(140 mM NaCl, 20 mM NaPhosphate, 0.05% Tween-20,
pH 7.2). After washing, the supernatant was removed
and 20 μl of RB solution (1% SDS in de-ionized H20)
was added and samples were incubated at 50°C for
10 minutes. After this initial incubation, 30 μl of
Laemmli buffer with 5% BME (Bio-Rad) was added to
each sample. Subsequently, samples were incubated at
50°C for 5 minutes and 70°C for 10 minutes. The
Dynabeads were then pelleted by centrifugation and
40 μl of supernatant from each sample was used for
SDS-PAGE. The capture and washing of the Dynabeads
was performed with a magnetic stand (Life Technolo-
gies, Grand Island, NY).
To remove impurities, samples were run approxi-
mately 1 cm into a 12% SDS-PAGE gel (Bio-Rad,
Hercules, CA). The proteins were then excised and
digested in-gel using the ProteaseMAX/Trypsin gold
system, following manufacturer protocols (Promega,
Madison, WI). The resulting solution of eluted peptides
was dehydrated to dryness by vacuum centrifugation
at 23°C.
Proteomic analyses were performed in the Oregon
State University MS facility and core. The LTQ-FT mass
spectrometer was operated using data-dependent MS/
MS acquisition with a MS precursor ion scan, performed
in the ICR cell, from 350-2000 m/z with the resolving
power set to 100,000 at m/z 400, and MS/MS scans
performed by the linear ion trap on the five most abun-
dant doubly or triply charged precursor ions detected in
the MS scan. A binary solvent system consisting of
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acid, and solvent B, acetonitrile with 0.1% formic acid
was used for the analyses. Tryptic peptides were loaded
onto a peptide trapping column (Cap Trap, Michrom)
and separated using a C18 column (Agilent Zorbax
300SB-C18, 250 x 0.3 mm, 5 μm). Peptides were trapped
and washed with 3% solvent B for 3 min at a flow rate of
5 μL/min. Peptide separation was achieved using a linear
gradient from 10% B to 30% B at a flow rate of 4 μL/min
over 102 minutes. LC-MS/MS analysis was conducted
on a Thermo LTQ-FT MS instrument coupled to a Wa-
ters nanoAcquity UPLC system.
Thermo RAW data files were processed with Proteome
Discoverer v1.3.0. For database searching Mascot (v2.3)
was used to search against the canine protein database
downloaded from NCBI website (http://www.ncbi.nlm.
nih.gov/). The following parameters were used for data-
base searching: the digestion enzyme was set to Trypsin/P
and two missed cleavage sites were allowed. The precursor
ion mass tolerance was set to 10 ppm, while fragment ion
tolerance of 0.8 Da was used. Dynamic modifications that
were considered: carbamidomethyl (+57.02 Da) for cyst-
eine and oxidation (+15.99 Da) for methionine, phosphor-
ylation (+97.98 Da) of serine, threonine and tyrosine and
biotinylation of lysine. Automatic target decoy search with
1% FRD was implemented into the Mascot search param-
eters. Scaffold_3.3.1 (Proteome Software, Portland, OR)
was used for search data compilation and data evaluation
with embedded X!Tandem database searching algorithm.
For protein validation, peptide identification probability
was set to 95% and protein identification probability was
set to 99%, and proteins with two or more peptide
matches were selected as true identifications [37].
qRT-PCR
Cells were grown to ~80% confluency on 10 cm2 tissue
culture plates, washed once with PBS and harvested into
1 mL of TRIzol reagent (Life Technologies, Grand Is-
land, NY, Grand Island, NY). RNA was isolated by the
manufacturer’s guidelines and the resulting RNA was
quantified with the NanoDrop ND-1000 instrument. For
cDNA synthesis 1000 ng of total RNA was reverse tran-
scribed using Double Primed RNA to cDNA EcoDry™
Premix (Clontech, Mountain View, CA). All qRT-PCR
assays were run in a total reaction volume of 10 μL com-
prised of 5 μL Power Sybr PCR Master Mix (Applied
Biosystems, Carlsbad, CA), 500 nM of both forward and
reverse primers and 1 μL of cDNA template. Real time
PCR was performed in MicroAmp optical 96-well reac-
tion plates using StepOnePlus Real-Time PCR Systems
(Applied Biosystems, Carlsbad, CA). The cycle threshold
(CT) for each gene of interest was normalized to
GAPDH. The resulting delta-CT value was used to de-
termine the relative quantification (RQ) of each geneusing 2^(-delta CT). All RQ values were then divided by
the RQ value of the highest expressing cell line and
multiplied by 100 to determine relative differences in ex-
pression levels between the cell lines. All qRT-PCR
primers were designed across exons in order to prevent
background signal from any contaminating genomic
DNA (Additional file 5: Table S5).
Western blot
Insoluble debris in the cell lysate was pelleted by centri-
fugation for 10 minutes at 10,000 RPM at 4°C. The
supernatant was then transferred to a new tube. Protein
concentrations were assessed by BCA assay (Thermo
Scientific, Rockford, IL). Approximately 5 μg of total
protein was run in each lane. Proteins were denatured in
Laemmli buffer with 5% BME (Bio-Rad, Hercules, CA)
and separated by SDS-PAGE. Proteins were transferred
to nitrocellulose films using the iBlot system (Life Tech-
nologies, Grand Island, NY). Primary antibodies
targeting Thrombospondin-1 (sc-12312), CD44 (sc-
18849), CYR61 (sc-8560), Notch 2 (sc-5545) and Plexin
B2 (sc-34504) and GAPDH (sc-166574) (Santa Cruz Bio-
technology, Santa Cruz, CA) were used at a dilution of
1:200 in PBS supplemented with 0.05% Tween-20 and
2% BSA. IRdye secondary antibodies (LI-COR, Lincoln,
NE) were used at a dilution of 1:10,000 in PBS
supplemented with 0.05% Tween-20 and 2% BSA. West-
ern blots were visualized and recorded on the LI-COR
scanning system (LI-COR, Lincoln, NE). To visualize
biotinylated proteins, streptavidin IRDye680 (LI-COR,
Lincoln, NE) was used for Western blot at a concentra-
tion of 1:10,000. To visualize total protein, samples were
separated by SDS-PAGE and visualized by silver stain
(Bio-Rad, Hercules, CA).
Immunocytochemistry
Cells were cultured to approximately 80% confluency in a
96-well plate. Cells were incubated with primary anti-
bodies (Rat IgG control (sc-2026), anti-CD44 (sc-18849),
goat IgG control (sc-2028), anti-Thrombospondin-1 (sc-
12312), CYR61 (sc-8560), anti-PlexinB2 (sc-34504), rabbit
IgG control (sc-2027) and anti-Notch2 (sc- sc-5545) at a
dilution of 1:200 in complete RPMI, at 4°C for 30 min
(Santa Cruz Biotechnology). Cells were washed then incu-
bated with secondary antibody, anti-rat-IgG-IRdye800
(926-32219), anti-goat-IgG-IRdye800 (926-32214) or anti-
rabbit-IgG-IRdye800 (926-32211) a dilution of 1:1000 in
complete RPMI, at 4°C for 30 min (LICOR). Cells were
then washed extensively, the media replaced with 50 μl
HBSS per well, and imaged on a LICOR scanner (LICOR).
Hoescht 33342 (Sigma) was then added at a concentration
of 2.5 μg/ml and incubated for 5 min at room temp. Cells
were then washed and the fluorescent signal from the
Hoeschst stain was read on a fluorescent plate reader. The
Milovancev et al. BMC Veterinary Research 2013, 9:116 Page 9 of 10
http://www.biomedcentral.com/1746-6148/9/116fluorescent signal from the secondary antibodies was then
normalized against the signal for Hoeschst, to account for
differences in the number of cells (Additional file 4). Each
condition had four technical replicates, which were used
to establish the error bars (standard deviation).
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
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Additional file 4: Primers used for quantitative real-time PCR of
cultured normal canine osteoblasts (CnOb) and two validated
canine osteosarcoma cell lines (POS and HMPOS).
Additional file 5: Table S5. Immunocytochemistry data sets. Complete
data, with all replicates and all tested antibodies, of
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